Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.
For more information on how to use this blog click here, the HCV drug pipeline click here, and for more information on HCV clinical trials click here
Saturday, May 18, 2013
HBV may increase risk for non-hodgkin lymphoma
Researchers from the Marshfield Clinic in Wisconsin conducted a meta-analysis that included 19 case-control studies performed throughout the world. The analysis included a total of 13,947 cases and 1,559,448 controls. In nine of the studies, the controls were non-lymphoma cancer/hospital patients; eight studies incorporated healthy controls, and two studies included both types of controls. In most of the studies (17), patients were diagnosed with hepatitis B by detection of HBsAg, while hepatitis B was self-reported in the remaining two studies. All incidences of non-hodgkin lymphoma (NHL) were diagnosed with histopathology.